Last reviewed · How we verify
300 IR
At a glance
| Generic name | 300 IR |
|---|---|
| Also known as | Sublingual immunotherapy tablet |
| Sponsor | Stallergenes Greer |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (PHASE1)
- Human Models of Selective Insulin Resistance: Alpelisib, Part I (PHASE1)
- Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma (PHASE3)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children (PHASE3)
- Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model (PHASE2)
- A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 300 IR CI brief — competitive landscape report
- 300 IR updates RSS · CI watch RSS
- Stallergenes Greer portfolio CI